Gülin Öz

,

Credentials

PhD

Bio

Dr. Gülin Öz is a Professor in the Department of Radiology, Center for Magnetic Resonance Research (CMRR). Following BS degrees in Physics and Chemistry and a PhD in Biochemistry, she continued with postdoctoral training at the CMRR where she later joined the faculty.

Dr. Öz uses high field, multi-nuclear magnetic resonance spectroscopy (MRS) to delineate neurochemical and metabolic alterations in neurodegenerative diseases and diabetes. She leads a program in spinocerebellar ataxias and has studied neurochemistry in Parkinson, Huntington, Alzheimer diseases and ALS. She co-led an effort by the MRS Consensus Group to provide guidelines for MRS data acquisition and analysis, quality assessment, and interpretation. She further led a multi-site Bioengineering Research Partnership (BRP) for across-platform harmonization of advanced MRS methods. She serves as PI of a Consortium to assess COVID-19 sequelae in the brain (COVID-BRAIN) and MPI of an international clinical trial readiness study (READISCA) that aims to validate MRI and MRS biomarkers in the earliest stages of neurodegeneration in spinocerebellar ataxias. Finally, she leads the MR Biomarkers Working Group of the Ataxia Global Initiative.

Selected Publications

Chandrasekaran J, Petit E, Park YW, du Montcel ST, Joers JM, Deelchand DK, Považan M, Banan G, Valabregue R, Ehses P, Faber J, Coupé P, Onyike CU, Barker PB, Schmahmann JD, Ratai EM, Subramony SH, Mareci TH, Bushara KO, Paulson H, Durr A, Klockgether T, Ashizawa T, Lenglet C, Öz G for the READISCA Consortium. Clinically meaningful Magnetic Resonance Endpoints Sensitive to Preataxic Spinocerebellar Ataxia Types 1 and 3. Ann Neurol, doi: 10.1002/ana.26573.

Deelchand DK, Henry PG, Joers JM, Auerbach EJ, Park YW, Ratai EM, Kantarci K, Öz G (2022) Plug-and-play Advanced Magnetic Resonance Spectroscopy. Magn Reson Med, 87(6):2613-2620.

Deelchand DK, Berrington A, Noeske R, Joers JM, Arani A, Gillen J, Schär M, Nielsen JF, Peltier S, Seraji-Bozorgzad N, Landheer K, Juchem C, Soher BJ, Noll DC, Kantarci K, Ratai EM, Mareci TH, Barker PB, Öz G (2021) Across-vendor standardization of semi-LASER for single voxel MRS at 3 Tesla. NMR Biomed, 34(5):e4218.

Öz G, Deelchand DK, Wijnen JP, Mlynárik V, Mekle R, Noeske R, Scheenen TWJ, Tkáč I and the Advanced Single Voxel ¹H MRS Working Group (2020) Advanced single voxel ¹H magnetic resonance spectroscopy techniques: Experts' consensus recommendations, NMR Biomed, e4236, DOI: 10.1002/nbm.4236.

Öz G, Harding IH, Krahe J, Reetz K (2020) MR Imaging and Spectroscopy in Degenerative Ataxias: Towards Multi-modal, Multi-site, Multi-stage Monitoring of Neurodegeneration, Curr Opin Neurol, 33(4):451-461.

Cheong I, Deelchand DK, Eberly LE, Marjańska M, Manousakis M, Guliani G, Walk D, Öz G (2019) Neurochemical Correlates of Functional Decline in Amyotrophic Lateral Sclerosis, J Neurol Neurosurg Psychiatry, 90(3):294-301.

Joers JM, Deelchand DK, LyuT, EmirUE, Hutter D, GomezCM, BusharaKO, Eberly LE, Öz G (2018) Neurochemical abnormalities in premanifest and early spinocerebellar ataxias, Ann Neurol, 83(4):816-829.

Park YW, Deelchand DK, Joers JM, Hanna B, Kantarci K, Soher BJ, Barker PB, Park HW, Öz G, Lenglet C (2018) AutoVOI: Real-time automatic prescription of volume-of-interest for single voxel spectroscopy, Magn Reson Med, 80(5):1787-1798.

Deelchand DK, Kantarci K, Öz G. (2018) Improved localization, spectral quality and repeatability with advanced MRS methodology in the clinical setting, Magn Reson Med, 79(3):1241-1250.

Öz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, Bolan PJ, Brindle KM, Cudalbu C, Dincer A, Dydak U, Emir UE, Frahm J, González RG, Gruber S, Gruetter R, Gupta RK, Heerschap A, Henning A, Hetherington HP, Howe FA, Hüppi PS, Hurd RE, Kantarci K, Klomp DWJ, Kreis R, Kruiskamp MJ, Leach MO, Lin AP, Luijten PR, Marjańska M, Maudsley AA, Meyerhoff DJ, Mountford CE, Nelson SJ, Pamir MN, Pan JW, Peet AC, Poptani H, Posse S, Pouwels PJW, Ratai EM, Ross BD, Scheenen TWJ, Schuster C, Smith ICP, Soher BJ, Tkáč I, Vigneron DB, Kauppinen RA. The MRS Consensus Group. (2014) Clinical Proton MR Spectroscopy in Central Nervous System Disorders, Radiology, 270(3):658-79.

Emir UE, Tuite PJ, Öz G (2012) Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla ¹H MRS, PLoS One, 7(1): e30918.

Emir UE, Auerbach EJ, Van De Moortele PF, Marjańska M, Ugurbil K, Terpstra M, Tkáč I, Öz G (2012) Regional neurochemical profiles in the human brain measured by ¹H MRS at 7 tesla using local B₁ shimming, NMR Biomed, 25: 152–160.

Öz G, Tkáč I (2011) Short-echo, single-shot, full-intensity ¹H MRS for neurochemical profiling at 4T: Validation in the cerebellum and brainstem, Magn Reson Med, 65(4):901-10.

Öz G, Nelson CD, Koski DM, Henry PG, Marjańska M, Deelchand DK, Shanley R, Eberly LE, Orr HT, Clark HB (2010) Noninvasive Detection of Pre-symptomatic and Progressive Neurodegeneration in a Mouse Model of Spinocerebellar Ataxia type 1, J Neurosci, 30:3831-3838.

Öz G, Kumar A, Rao JP, Kodl CT, Chow L, Eberly LE, Seaquist ER (2009) Human Brain Glycogen Metabolism during and following Hypoglycemia, Diabetes, 58(9):1978-85.

Tkáč I, Öz G, Adriany G, Uğurbil K, Gruetter R (2009) In vivo ¹H NMR spectroscopy of the human brain at high magnetic fields: Metabolite quantification at 4T vs. 7T, Magn Reson Med, 62:868–879.

Öz G, Seaquist ER, Kumar A, Criego A, Benedict LE, Rao JP, Henry PG, van de Moortele PF, Gruetter R (2007) Human Brain Glycogen Content and Metabolism: Implications on its Role in Brain Energy Metabolism, Am J Physiol Endocrinol Metab, 292(3): E946-51

Öz G, Berkich DA, Henry PG, Xu Y, LaNoue K, Hutson SM, Gruetter R (2004) Neuroglial metabolism in the awake rat brain: CO₂ fixation increases with brain activity, J Neurosci, 24: 11273-11279.

Research Summary

Dr. Öz’s research interests are:

• To develop high and ultrahigh field MRI and MRS methodology for human and rodent applications.
• To establish in vivo MRI and MRS biomarkers of neurodegeneration, in parallel studies with patients and transgenic mouse models. Such biomarkers are expected to facilitate early disease detection and treatment monitoring in pre-clinical and clinical trials.
• To determine the effects of diabetes and the hypoglycemic consequences of intensive insulin therapy on brain glucose and glycogen metabolism and to elucidate pathogenic mechanisms of impaired awareness of hypoglycemia using MRS.